

EXHIBIT B

Express Mail No.: EM 061 023 892 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Palese et al.

Application No.: 08/444,994

Filed: May 19, 1995

For: IDENTIFICATION AND USE OF
ANTIVIRAL COMPOUNDS THAT
INHIBIT INTERACTION OF HOST
CELL PROTEINS AND VIRAL
PROTEINS REQUIRED FOR VIRAL
REPLICATION

Art Unit: 1648

Examiner: Parkin, J.

Attorney Docket No.: 6923-054

JAN 30 2001

RECEIVED

PETITION FOR EXTENSION OF TIME UNDER 37 CFR § 1.136(a)

Assistant Commissioner for Patents
Box Missing Parts
Washington, D.C. 20231

Sir:

It is respectfully requested that the time for response to the Office Action dated July 19, 1999, be extended for a period of five months from August 19, 1999 to and including January 19, 2000.

The fee for this extension is estimated to be \$925.00. Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.

Respectfully submitted,

by *Joergeline Bern*
Reg No 43,492

Date January 14, 2000

Laura A. Coruzzi 30,742
Laura A. Coruzzi (Reg. No.)
PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, N.Y. 10036-2711
(212) 790-9090

Express Mail No.: EM 061 023 892 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Palese et al.

Application No.: 08/444,994

Filed: May 19, 1995

For: IDENTIFICATION AND USE OF
ANTIVIRAL COMPOUNDS THAT
INHIBIT INTERACTION OF HOST
CELL PROTEINS AND VIRAL
PROTEINS REQUIRED FOR VIRAL
REPLICATION

Art Unit: 1648

Examiner: Parkin, J.

Attorney Docket No.: 6923-054

JAN 30 2001

PENNIE & EDMONDS LLP

PETITION FOR EXTENSION OF TIME UNDER 37 CFR § 1.136(a)

Assistant Commissioner for Patents
Box Missing Parts
Washington, D.C. 20231

Sir:

It is respectfully requested that the time for response to the Office Action dated July 19, 1999, be extended for a period of five months from August 19, 1999 to and including January 19, 2000.

The fee for this extension is estimated to be \$925.00. Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.

Respectfully submitted,

by Josephine Berni Reg No 43,492Date January 14, 2000Laura A. Coruzzi 30,742
Laura A. Coruzzi (Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, N.Y. 10036-2711
(212) 790-9090

PALESE *et al.*
Appl.No. 08/444,994

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

PALESE *et al.*

Appl. No. 08/444,994

Filed: May 19, 1995

For: IDENTIFICATION AND USE OF
ANTIVIRAL COMPOUNDS THAT
INHIBIT INTERACTION OF HOST
CELL PROTEINS AND VIRAL
PROTEINS REQUIRED FOR VIRAL
REPLICATION

Art Unit: 1648

Examiner: Parkin, J.

Atty. Dkt.: 6923-0054

PAID BY DEPT. OF COMMERCE

JAN 30 2001

ADMINISTRATIVE

PROVISIONAL ELECTION WITH TRAVERSE
UNDER 37 C.F.R. § 1.143

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Restriction Requirement dated July 19, 1999, and in accordance with Rules 111 and 143 of the Rules of Practice please consider the following provisional election, with traverse. A Petition To Extend Time accompanied by appropriate fee, is submitted concurrently herewith.

Remarks

Applicant received an Office Action dated July 19, 1999, which contained a requirement for restriction in connection with the application captioned above. More specifically, the Examiner has required a restriction under 35 U.S.C. § 121 to one of twelve different groups of claims.

Applicants hereby provisionally elect, with traverse, to prosecute the invention of Group I, Claims 1-8, 11-17, and 48, drawn to an assay for identifying inhibitors of influenza virus nucleoprotein-host cell protein binding interactions. Applicants note that Claims 4-10 were withdrawn from consideration as being drawn to non-elected species (*see*, Provisional Election, filed on January 13, 1997 and the Office Action, dated March 27, 1999). Thus, Group I should consist of Claims 1-3, 11-17 and 48.

Applicants respectfully request that the Examiner withdraw the requirement for restriction so that the claims are all examined together. At the very least, Applicants respectfully request that the requirement for restriction be modified so that only a species election is required, in which case, Applicants provisionally elect, with traverse, the species of Group I, as set forth in the Restriction Requirement.

The claims in Groups I-XII are all drawn to assays for identifying compounds that inhibit viral protein-host cell protein interactions. Moreover, it is noted that the Examiner has cited M.P.E.P. 806.04 and 808.01 as a basis for the restriction requirement. Applicants respectfully submit that these sections, in contrast to the Examiner's contention, support the examination of all the pending claims in the instant application.

Section 806.04 of the M.P.E.P. relates to "Independent Inventions." However, the Examiner has not shown how any of the provisions of this section demonstrate that the groups identified by the Examiner are indeed independent inventions. To the contrary, subsection 806.04(d) clearly indicates that Claim 1 of the instant application is a proper generic claim. In particular, this subsection states:

It is not possible to define a generic claim with that precision existing in the case of a geometrical term. In general, a generic claim should include no material element additional to those recited in the species claims, and must

comprehend within its confines the organization covered in each of the species.

For the purpose of obtaining claims to more than one species in the same case, the generic claim cannot include limitations not present in each of the added species claims. Otherwise stated, the claims to the species which can be included in a case in addition to a single species must contain all the limitations of the generic claims.

M.P.E.P. § 806.04(d). Claim 1 of the instant application clearly meets this standard for a proper generic claim encompassing the species of its dependent claims.

Reconsideration of the Restriction Requirement is also supported by § 808.01 of the M.P.E.P., cited by the Examiner. In particular, this section states:

Where the inventions claimed are independent, i.e., where they are not connected in design, operation, or effect under the disclosure of the particular application under consideration (MPEP § 806.04), *the facts relied on for this conclusion are in essence the reasons for insisting upon restriction. This situation, except for species, is but rarely presented*, since persons will seldom file an application containing disclosures of independent things.

M.P.E.P. § 806.04 (italicized emphasis in original, underlined emphasis added). Indeed, the instant application does not contain disclosures to "independent things," but rather discloses, *inter alia*, novel assay systems for inhibitors of viral-host cell protein interactions that apply to a variety of different proteins. Applicants respectfully submit, as clearly suggested by the passage from § 806.04 quoted above, that at most, the groups identified by the Examiner are species of the invention set forth in claim 1.

In fact, a restriction requirement as well as a species election has already been required by the U.S. Patent and Trademark Office, and made by the Applicants, in connection with the prosecution of the instant application (see, Office Action, dated September 13, 1996). Indeed, Group I in the present Restriction Requirement corresponds to the Group I, species A election made by the Applicants in their response to the first Restriction

- 4 -

PALESE *et al.*
Appl.No. 08/444,994

Requirement (*see*, Provisional Election, filed on January 13, 1997). Thus, the entire scope of Claim 1 has already been under active consideration, including searches by the Examiner and responses by the Applicants, in connection with the prosecution of the instant application.

In order for a requirement for restriction to be proper, M.P.E.P. § 803 states that there "must be a serious burden on the examiner" in the absence of the requirement (emphasis added). Thus, in view of M.P.E.P. § 803, all of the subject matter in Groups I-XII should be examined together, especially if any rejections specific to the subject matter of Group I are overcome. Even if the subject matter of these groups are distinct inventions, as asserted by the Examiner, it would not be a "serious burden" on the Examiner to search these groups in this application.

In summary, Applicants have demonstrated that the subject matter of the claims of Groups I-XII should be examined in the same application. Applicants request, therefore, that the restriction requirement be withdrawn, or, at the very least, modified such that only a species election is required.

Applicants reserve the right to petition from the restriction requirement under 37 C.F.R. § 1.144.

Respectfully submitted,

by: *Jeaneline Berni*
Reg No 43,492Date: January 14, 2000*Laura A. Coruzzi* 30,742
Laura A. Coruzzi. *JS* (Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090